• 中国科学论文统计源期刊
  • 中国科技核心期刊
  • 美国化学文摘(CA)来源期刊
  • 日本科学技术振兴机构数据库(JST)

临床输血与检验 ›› 2026, Vol. 28 ›› Issue (5): 717-725.DOI: 10.3969/j.issn.1671-2587.2026.05.008

• 临床输血 • 上一篇    下一篇

制备方法对重组单采血小板输注疗效和安全性的影响

张利1, 易海2, 马蕾2, 甘新宇1, 刘丽萍1, 漆宇1, 谭强1, 黎欢1, 任丽娜1, 彭涛1   

  1. 1中国人民解放军西部战区总医院输血医学科,四川成都 610083;
    2中国人民解放军西部战区总医院血液科,四川成都 610083
  • 收稿日期:2026-09-18 修回日期:2026-10-08 出版日期:2026-10-20 发布日期:2026-11-11
  • 通讯作者: 彭涛,主要从事输血医学研究,(E-mail)tao_1226@126.com。
  • 作者简介:张利,主要从事临床输血与输血相关检验研究,(E-mail)1062747632@qq.com。

The Influence of Preparation Methods on the Efficacy and Safety of Recombinant Apheresis Platelet Transfusion

ZHANG Li1, YI Hai2, MA Lei2, GAN Xinyu1, LIU Liping1, QI Yu1, TAN Qiang1, LI Huan1, REN Lina1, PENG Tao1   

  1. 1Department of Blood Transfusion, Chengdu 610083;
    2Department of Hematology, The General Hospital of Western Theater Command, Chengdu 610083
  • Received:2026-09-18 Revised:2026-10-08 Online:2026-10-20 Published:2026-11-11

摘要: 目的 探索两种制备方法对重组单采血小板输注疗效和安全性的影响,为该成分的临床应用提供数据支持。方法 前瞻性纳入104名血小板输注指征明确的血液病患者,在ABO同型血小板缺乏时予重组单采血小板输注,根据重组单采血小板制备方法分为离心组和单采组,比较两组患者的输注疗效和安全性。结果 104人进行了266次重组单采血小板输注,离心组和单采组分别输注157次和109次,离心组vs单采组:单次输注(0.98±0.08)治疗量vs(0.96±0.09)治疗量,12 h血小板计数增量9.5(2,18)×109/L vs 9(3,17)×109/L、12 h CCI 6.08(1.45,12.19)vs 6.02(1.19,11.81),输注有效率57.32% vs 64.22%,下次血小板输注间隔50.75(24.88,95.53)h vs 49.3(26.58,101.35)h,输注不良反应率0 vs 0.92%,组间差异均无统计学意义(P>0.05)。离心组制备不良事件发生率较单采组高(4.46% vs 0),血小板采集到输注的时间间隔2(1,3)天较单采组0(0,1)天长,血小板输注等待时长6.07(3.55,9.45)小时较单采组8.35(4.99,10.14)小时短,住院期间输注重组单采血小板1(1,3)次较单采组1(1,2)次多,住院期间输注血小板7.80(4.00,10.60)治疗量较单采组6.00(3.6,8.8)治疗量多,差异均有统计学意义(P<0.05)。回归分析和中介分析显示,两种制备方法对输注疗效(OR 1.03—1.34,P>0.05)和安全性(OR 1.99—4.35,P>0.05)的影响无统计学差异。结论 ABO同型血小板缺乏时,离心或单采制备的重组单采血小板均可用于血液病患者临床输注,实际应用时需综合库存、紧急程度、患者血型、捐献者血型和数量等因素选择。

关键词: 重组单采血小板, 输血疗效, 不良事件, 输血不良反应, 制备方法

Abstract: Objective This study aims to investigate the impact of two distinct preparation methods on the efficacy and safety of recombinant apheresis platelet transfusion, thereby providing empirical data to support its clinical application. Methods A prospective study was conducted involving 104 patients diagnosed with hematological disorders who had clear indications for platelet transfusion. Recombinant apheresis platelets were administered in cases where ABO-compatible platelets were unavailable. Based on the preparation method, the recombinant apheresis platelets were categorized into two groups: the centrifugation group and the apheresis group. The efficacy and safety of transfusions were subsequently compared between two groups. Results A total of 266 recombinant apheresis platelet transfusions were administered to the 104 patients. The centrifugation group enrolled 157 transfusions, while the apheresis group enrolled 109 transfusions. The comparison between the centrifugation and apheresis groups revealed the following: the average volume per single infusion was 0.98±0.08 for the centrifugation group and 0.96±0.09 for the apheresis group. The 12-hour post-transfusion platelet count increment was 9.5 (2, 18)×109/L for the centrifugation group and 9 (3, 17)×109/L for the apheresis group. In a comparative analysis of the two groups, the 12-hour Corrected Count Increment (CCI) was 6.08 (95%CI: 1.45, 12.19) versus 6.02 (95%CI: 1.19, 11.81), with infusion efficiencies of 57.32% and 64.22%, respectively. The subsequent platelet infusion intervals were 50.75 hours (95%CI: 24.88, 95.53) compared to 49.3 hours (95%CI: 26.58, 101.35). The rate of infusion-related adverse reactions was 0% in one group versus 0.92% in the other, with no statistically significant difference observed between the groups (P>0.05). However, the incidence of adverse events was higher in the centrifugation group at 4.46% compared to 0% in the apheresis group. The interval between platelet collection and transfusion was 2 days (range: 1-3 days) longer in the centrifugation group compared to 0 days (range: 0-1 day) in the apheresis group. The waiting time for platelet transfusion was reduced by 6.07 hours (95%CI: 3.55, 9.45) in the centrifugation group compared to 8.35 hours (95%CI: 4.99, 10.14) in the apheresis group. The number of recombinant apheresis platelet transfusions during hospitalization was 1 (range: 1-3) in the centrifugation group, which was higher than 1 (range: 1-2) in the apheresis group. Additionally, the total volume of platelet transfusion treatment during hospitalization was 7.80 units (95%CI: 4.00, 10.60) in the centrifugation group, exceeding the 6.00 units (95%CI: 3.6, 8.8) in the apheresis group.The regression analysis and mediation analysis indicated that there was no statistically significant difference in infusion efficacy [Odds Ratio (OR) 1.03—1.34, P>0.05] and safety (OR 1.99—4.35, P>0.05) between the two preparation methods. Conclusion Recombinant apheresis plateletsprepared through either centrifugation or apheresis are suitable for clinical infusion in patients with hematological disorders when ABO identical platelet is deficient. In practical applications, considerations such as current platelet inventory, infusion time constraints, patient blood type, donor blood type and quantity should be taken into account.

Key words: Recombinant apheresis platelets, Transfusion efficacy, Adverse event, Adverse transfusion reactions, Methods of preparation

中图分类号: